MYELOMATCH
OPEN TO ACCRUAL
MSRP for Tier Advancement in the NCI myeloMATCH Trials
UW19086
OPEN TO ACCRUAL
LTFU Protocol for Subjects Treated with Gene-Modified T Cells
UW22087
OPEN TO ACCRUAL
Phase II Study of Venetoclax-Obinutuzumab Retreatment in Patients with Recurring CLL
UW23093
OPEN TO ACCRUAL
Ph 1 Study of Venetoclax/Aza or Venetoclax in Combo w/ Ko-539 or 7+3 in combo w/Ko-539 in AML
UW23129
OPEN TO ACCRUAL
Ph1 Dose-Escalation Trial of Mesenchymal Stromal Cells in pts w Medical Xerostomia
UW24000
OPEN TO ACCRUAL
Ph1/3 study on efficacy and safety of selinexor in combo with ruxolitinib in pts w myelofibrosis
UW24056
OPEN TO ACCRUAL
PH1/1b Study of CLK Inhibitor BH-30236 in Adutls with R/R AML or HR-MDS